Independent public reference library

Ageing biology, biomarkers, interventions, and research literacy.

Subgroup Analyses and Effect Modification in Longevity Research

Key Takeaways

Who This Is Useful For

This page is useful for readers evaluating claims that an ageing-related association or intervention works differently in people defined by age, sex, frailty, disease burden, genotype, baseline biomarker, or predicted risk. These analyses can identify genuine heterogeneity, but methodological reviews show that they are also frequently overinterpreted or incompletely reported. [1] [3] [9]

Most studies report an average association or average intervention effect across all participants. Subgroup analysis examines whether that estimate changes across levels of another variable. When the effect truly varies across those levels, the pattern is commonly called effect modification or heterogeneity of effect; in a statistical model it is often represented by an interaction term. [2] [5] [10]

The question is relevant to longevity research because people of the same chronological age can differ in baseline disease risk, frailty, organ function, and biomarker profiles. Such differences may change absolute outcomes even when a relative association is similar, and they may sometimes alter the size or direction of an exposure or intervention effect. [5] [6]

Subgroups, Effect Modification, and Interaction

The terms overlap but are not identical. A subgroup is simply a subset of participants. Effect modification describes a result in which the effect of one exposure varies across values of another characteristic. Interaction can refer to the statistical term used to estimate that variation or to a causal question about the joint effects of two exposures. The intended meaning and effect scale should therefore be stated rather than inferred from the word alone. [5] [10]

Term What It Describes Longevity-Research Example Main Caution
Subgroup analysis An analysis within categories of a participant characteristic Reporting a biomarker-outcome association separately below and above age 75 Separate estimates do not establish that the estimates differ [1]
Effect modification Variation in an effect measure across levels of another variable A different risk difference across frailty strata The conclusion can change with the effect scale [5]
Statistical interaction A model term testing departure from a specified joint-effect model An intervention-by-baseline-risk term in a regression model Its meaning depends on model form and scale [5] [10]
Heterogeneity of treatment effect Variation in intervention effects among people or identifiable groups Different absolute benefit across levels of predicted mortality risk One variable at a time may not capture joint differences in baseline risk [6]

The Correct Comparison Is Between Subgroups

A common error is to conclude that effects differ because one subgroup has a P value below 0.05 and another has a P value above 0.05. Those P values answer separate within-subgroup questions. They do not directly test the difference between the two effect estimates. A formal interaction test evaluates that between-subgroup contrast, while subgroup-specific estimates and confidence intervals show its size and precision. [1] [4] [11]

For the same reason, a forest plot should not be read by scanning only for which subgroup confidence intervals cross the null value. The interaction estimate, its confidence interval, the number of tests, and the prior rationale for the subgroup are more informative than a visual contrast between isolated significance labels. [2] [4]

Why the Effect Scale Matters

Effect modification is scale-specific. Suppose two groups have the same relative risk reduction but different baseline risks. The higher-risk group will generally have a larger absolute risk reduction, so there may be modification on the absolute scale without modification on the relative scale. Additive measures such as risk differences and multiplicative measures such as risk ratios therefore answer different questions. [5] [10]

This distinction is especially important in older or frailer populations, where baseline event risks can vary substantially. A paper should identify the scale used, report subgroup-specific event rates or effect estimates, and avoid describing one scale as if it were universal. [5] [6]

What Makes a Subgroup Claim More Credible?

Credibility Check Stronger Evidence Reason for Caution
Timing of the hypothesis Specified in the protocol or analysis plan before outcomes were examined A data-derived subgroup is more vulnerable to chance patterns and selective emphasis [2] [4]
Number of analyses A small, justified set of subgroup questions Testing many variables and cutpoints increases opportunities for false-positive findings [2] [3]
Statistical evidence An interaction estimate with a confidence interval, alongside subgroup effects Within-subgroup significance tests do not compare the subgroups [1] [8]
Prior support A stated direction supported by earlier biological or epidemiological evidence A plausible story constructed after seeing the result is weak corroboration [2]
Consistency A similar pattern across related outcomes or independent studies An isolated finding may not replicate [2] [3]

Multiplicity and Limited Power

Subgroup analysis faces two opposing statistical problems. Trying many subgroup variables, alternative cutpoints, outcomes, and models increases the chance of finding an apparently notable result. Yet each subgroup contains fewer observations than the full sample, and tests of interaction often have limited power, producing wide confidence intervals and making real differences difficult to distinguish from random variation. [2] [3] [8]

A non-significant interaction is therefore not proof that all groups have exactly the same effect, while a single significant interaction among many tests may be a chance result. The number of analyses, the precision of the interaction estimate, and any multiplicity strategy belong in the interpretation. [2] [8]

Continuous Characteristics Should Not Be Reduced Carelessly

Age, frailty scores, inflammatory markers, and biological-age measures are often continuous. Splitting them at a convenient or data-selected threshold discards information, reduces power, and can create an artificial step where the underlying pattern is gradual. Searching for an “optimal” cutpoint adds further bias. Models that retain the continuous variable and allow plausible non-linear relationships can give a more informative account of effect modification. [7]

Categories can still be useful for presentation when they have a prior scientific or clinical basis, but readers should check whether the boundary was prespecified, whether results are robust to other modeling choices, and whether the continuous interaction is also shown. [4] [7]

Trials and Observational Studies Require Different Cautions

In a randomized trial, treatment assignment is randomized, but the characteristic defining a subgroup usually is not. Baseline-defined interaction analyses preserve the randomized treatment comparison within each subgroup, whereas subgroups defined by events after randomization can introduce selection bias. Prespecification and a suitable interaction model remain important. [2] [4]

In observational longevity research, both the exposure and proposed modifier may be associated with other determinants of the outcome. Confounding must be considered for the stratum-specific effect being estimated, and an apparent modifier can sometimes be a proxy for another causal or contextual factor. Effect modification is descriptive of the estimated contrast; it does not by itself identify the biological reason for the difference. [10] [12]

How to Read a Subgroup Result

Practical Interpretation Examples

What This Does Not Mean

Related Reading

Summary

Subgroup analyses can show where an average result conceals meaningful variation, but they are most informative when the subgroup question was planned, the modifier was measured appropriately, the number of tests was limited, and the analysis directly compared effects on a stated scale. In longevity research, claims about differences by age, sex, frailty, risk, or biomarker status should be read from the interaction estimate and its uncertainty, then weighed against multiplicity, power, confounding, biological rationale, and replication. [2] [4] [5] [6]

References

  1. Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007). New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMsr077003
  2. Sun, X., Briel, M., Walter, S. D., & Guyatt, G. H. (2010). BMJ. https://www.bmj.com/content/340/bmj.c117.long
  3. Sun, X., et al. (2012). BMJ. https://www.bmj.com/content/344/bmj.e1553
  4. Hopewell, S., et al. (2025). BMJ. https://www.bmj.com/content/389/bmj-2024-081124
  5. Knol, M. J., & VanderWeele, T. J. (2012). International Journal of Epidemiology. https://academic.oup.com/ije/article/41/2/514/692957
  6. Kent, D. M., Rothwell, P. M., Ioannidis, J. P. A., Altman, D. G., & Hayward, R. A. (2010). Trials. https://pmc.ncbi.nlm.nih.gov/articles/PMC2928211/
  7. Royston, P., Altman, D. G., & Sauerbrei, W. (2006). Statistics in Medicine. https://pubmed.ncbi.nlm.nih.gov/16217841/
  8. Brookes, S. T., Whitely, E., Egger, M., Davey Smith, G., Mulheran, P. A., & Peters, T. J. (2004). Journal of Clinical Epidemiology. https://pubmed.ncbi.nlm.nih.gov/15066682/
  9. Schandelmaier, S., et al. (2014). BMJ. https://www.bmj.com/content/349/bmj.g4539
  10. VanderWeele, T. J., & Knol, M. J. (2014). Epidemiologic Methods. https://www.degruyter.com/document/doi/10.1515/em-2013-0005/html
  11. Pocock, S. J., Assmann, S. E., Enos, L. E., & Kasten, L. E. (2002). Statistics in Medicine. https://onlinelibrary.wiley.com/doi/10.1002/sim.1296
  12. VanderWeele, T. J. (2012). Epidemiology. https://pmc.ncbi.nlm.nih.gov/articles/PMC4249691/
Educational Disclaimer

This content is provided for educational purposes only and does not constitute medical advice.